10th Anniversary of JCDD—Modern Diagnostic and Therapeutic Strategies in Advanced Heart Failure and Heart Transplantation

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Cardiovascular Clinical Research".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 2817

Special Issue Editors


E-Mail
Guest Editor
1. Clinical Ergospirometry, Exercise and Rehabilitation Laboratory, National and Kapodistrian University of Athens, 106 75 Athens, Greece
2. Cardiac Surgery ICU, Onassis Cardiac Surgery Center, 176 74 Athens, Greece
Interests: exercise training; rehabilitation; cardiopulmonary exercise testing; critical illness; heart failure; pulmonary hypertension; cardiac surgery; extracorporeal membrane oxygenation (ECMO)
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Clinical Therapeutics, Faculty of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, Greece
Interests: advanced heart failure; transplantation; cardio-oncology; pulmonary hypertension
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Section of Heart Failure & Transplantation, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Interests: advanced heart failure; transplantation; pulmonary hypertension; left ventricle assist device

Special Issue Information

Dear Colleagues,

This Special Issue of the Journal of Cardiovascular Development and Disease entitled 10th Anniversary of JCDD—Modern Diagnostic and Therapeutic Strategies in Advanced Heart Failure and Heart Transplantation focuses on the recent advances in the field of Advanced Heart Failure and Heart Transplantation. During the last decades there have been an increasing number of patients with heart failure due to increased coronary heart disease-main cause of heart failure, but also in advances in diagnosis with the modern genetic, biochemical, echocardiographic and haemodynamic assessment. New diagnostic methods have contributed to the early diagnosis and risk stratification of heart failure with emphasis in advanced heart failure prognostic tools. Great interest has been emerging from the diagnostic challenges for Heart Failure with preserved ejection fraction and exercise haemodynamics during Cardiopulmonary Exercise Testing seems to play a significant role. On the other hand despite limited progress has been noted on Heart Failure medical therapy, there is growing evidence of the value of the short (ECMO, IMPELLA, TandemHeart) and long term mechanical assist devices (LVAD/BiVADs) as a bridge to heart transplantation, destination therapy, recovery or even organ donors. The necessity of increasing the organ donors has oriented clinicians towards donors after circulatory death (DCD) harvesting that has been increasing significantly during the last decade offering an alternative to the limited number of donors after brain death (DBD).

We are pleased to invite authors to submit original research articles, recommendation articles, and reviews covering all aspects of Advanced Heart Failure and Heart Transplantation, from diagnosis to clinical management and treatment.

In order to evaluate and organize the content of the Special Issue, please let us know the preliminary title of your paper, the type of paper that you plan to submit (research original article, review or case report) and any other additional information that would be useful. All manuscripts of original research that fit the scope of this Special Issue are welcome. For reviews, a direct co-operation between the authors and the Guest Editors would be useful to avoid thematic overlaps.

Participation in this Special Issue through the submission of a manuscript could be an excellent opportunity for primary researchers to enrich their CV, for doctoral or post-doctoral trainees to gain experience in writing reviews and for institutions to present their high quality original research in a high-quality journal.

Dr. Stavros Dimopoulos
Dr. Alexandros Briasoulis
Dr. Paulino A. Alvarez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • heart transplantation
  • ECMO
  • impella
  • tandemHeart
  • cardiogenic shock
  • cardiopulmonary exercise testing
  • exercise training
  • organ donation
  • echocardiography
  • haemodynamics
  • right ventricle dysfunction
  • IABP

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 1326 KiB  
Review
Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices
by Michael Antonopoulos, Michael J. Bonios, Stavros Dimopoulos, Evangelos Leontiadis, Aggeliki Gouziouta, Nektarios Kogerakis, Antigone Koliopoulou, Dimitris Elaiopoulos, Ioannis Vlahodimitris, Maria Chronaki, Themistocles Chamogeorgakis, Stavros G. Drakos and Stamatis Adamopoulos
J. Cardiovasc. Dev. Dis. 2024, 11(2), 61; https://doi.org/10.3390/jcdd11020061 - 16 Feb 2024
Viewed by 2434
Abstract
Heart Failure is a chronic and progressively deteriorating syndrome that has reached epidemic proportions worldwide. Improved outcomes have been achieved with novel drugs and devices. However, the number of patients refractory to conventional medical therapy is growing. These advanced heart failure patients suffer [...] Read more.
Heart Failure is a chronic and progressively deteriorating syndrome that has reached epidemic proportions worldwide. Improved outcomes have been achieved with novel drugs and devices. However, the number of patients refractory to conventional medical therapy is growing. These advanced heart failure patients suffer from severe symptoms and frequent hospitalizations and have a dismal prognosis, with a significant socioeconomic burden in health care systems. Patients in this group may be eligible for advanced heart failure therapies, including heart transplantation and chronic mechanical circulatory support with left ventricular assist devices (LVADs). Heart transplantation remains the treatment of choice for eligible candidates, but the number of transplants worldwide has reached a plateau and is limited by the shortage of donor organs and prolonged wait times. Therefore, LVADs have emerged as an effective and durable form of therapy, and they are currently being used as a bridge to heart transplant, destination lifetime therapy, and cardiac recovery in selected patients. Although this field is evolving rapidly, LVADs are not free of complications, making appropriate patient selection and management by experienced centers imperative for successful therapy. Here, we review current LVAD technology, indications for durable MCS therapy, and strategies for timely referral to advanced heart failure centers before irreversible end-organ abnormalities. Full article
Show Figures

Figure 1

Back to TopTop